Developer docs
API playgroundTry for free, no card

Search company profiles

GalenusRx

Full company profile

uuid0002gq6

Namestring
GalenusRx
Legal namestring
GalenusRx, Inc.
Websiteurl
galenusrx.com
Company typeenum
Private
Founded yearint
2023
Descriptiontext

GalenusRx, Inc. is a privately held healthcare technology company founded in 2023 and headquartered in Montverde, Florida (incorporated in Delaware). The company develops and commercializes the APPRAISE (Actionable PolyPharmacy Risk Assessment Index for Safety and Efficacy) platform, a proprietary medication safety system that uses quasi-mechanistic predictive algorithms to simultaneously analyze drug-drug, multi-drug, drug-gene, and drug-disease interactions, producing personalized risk assessments individualized to a patient's DNA profile. APPRAISE is delivered primarily through a subscription service called Lifesaving Insights, which combines pharmacogenomic (PGx) testing — an at-home cheek swab analyzing approximately 100 gene variants — with consultations from Precision Clinical Pharmacists who generate tailored medication recommendations.

The company operates a dual-channel go-to-market: enterprise field sales targeting health systems, ACOs, payers, reinsurance intermediaries, pharmaceutical companies, and hospice providers, alongside a direct-to-consumer motion through the company website. Distribution is augmented by strategic channel partnerships with Hannover Re US (reinsurance), healthŌme (PGx testing), Kadance (pharmacogenomics ecosystem), and the Florida Association of ACOs (ACO network). Pricing is subscription-based on an annual billing cadence, with no publicly disclosed price points; enterprise contracts appear to be quote-based.

The business is led by founders Jacques Turgeon (CEO & CSO) and Veronique Michaud (President & COO), both internationally recognized pharmacotherapy researchers with combined $92M+ in research funding and 300+ peer-reviewed publications, alongside co-founder Peter Panageas (CSO/Commercial), Co-CEO Calvin H. Knowlton, Co-Founder Orsula Knowlton, and an advisory board of approximately 9 members including former FDA Office of Clinical Pharmacology Director Lawrence Lesko. The company has raised approximately $8 million across SEC Form D exempt securities offerings in 2024 and 2026, and was awarded an NIH SBIR grant in November 2025. GalenusRx maintains HIPAA compliance and has earned recognition including USA TODAY Network's 2024 Florida Startups to Watch.

Short descriptiontext

GalenusRx is a medication safety technology company that offers the APPRAISE platform, using predictive algorithms to analyze drug-drug, drug-gene, and drug-disease interactions for personalized risk assessment, serving health systems, payers, ACOs, pharmaceutical companies, and consumers via subscription.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersOrlando, United States
HQ citystring
Orlando
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medication safety analytics, pharmacogenomic testing, polypharmacy risk management, adverse drug event prevention, clinical decision support
Industry4 codes
PRIMARYHLAAANAB
Pharmacogenomics (PGx) Decision Support
SECONDARYHLACAKAK
Medication Safety, Pharmacovigilance & Adverse Event Reporting IT
Healthcare & Life Sciences/Digital Health & Health IT/ePrescribing, Medication Management & Pharmacy IT
SECONDARYHLACAKAH
Medication Therapy Management (MTM) & Clinical Pharmacy Services Tools
Healthcare & Life Sciences/Digital Health & Health IT/ePrescribing, Medication Management & Pharmacy IT
SECONDARYHLAFALAN
Pharmacovigilance, Medication Safety & Controlled Substance Diversion Monitoring
Healthcare & Life Sciences/Healthcare Providers & Systems/Pharmacy & Medication Management Services
NAICS code1 code
  • Medical Laboratories621511
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Medication Safety Analytics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Lifesaving Insights Subscription
TypeSubscription Recurring
Description

Subscription-based technology and consulting service providing personalized medication safety assessments, PGx testing interpretation, and ongoing pharmacist consultations. B2B and B2C models depending on channel (direct consumers, health systems, payers, pharma).

galenusrx.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details1 tier
1Subscription-based service; specific pricing tiers not publicly disclosed.
ModelSubscriptionBilling cadenceAnnual
Notes

Lifesaving Insights is described as a subscription-based technology and consulting service. No specific pricing tiers, price points, or billing amounts are publicly disclosed on the company website.

galenusrx.com
GTM typeB2B and B2C
B2B and B2C
Offering typeSoftware
Software
Brand1 of 2 records shown
1APPRAISE
Description

Actionable PolyPharmacy Risk Assessment Index for Safety and Efficacy - proprietary platform that analyzes drug-drug, multi-drug, drug-gene, and drug-disease interactions to provide comprehensive risk assessment individualized down to DNA.

galenusrx.com
+1 more record
Core offering1 text field

GalenusRx provides a proprietary medication safety assessment platform (APPRAISE) that analyzes drug-drug, multi-drug, drug-gene, and drug-disease interactions to deliver personalized risk scores individualized down to the DNA. Its Lifesaving Insights subscription service combines this platform with at-home pharmacogenomic (PGx) testing and Precision Clinical Pharmacist consultations to prevent adverse drug events, optimize medication regimens, and reduce polypharmacy-related hospitalizations across patients, providers, payers, ACOs, pharmaceutical companies, and hospices.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 3:1 or greater ROI for value-based care clients
+3 more records
Product overview1 text field

GalenusRx is a medication safety organization offering a unified platform plus modules architecture centered on two core products: the APPRAISE Platform and Lifesaving Insights subscription service. APPRAISE is a proprietary medication safety assessment platform that analyzes drug-drug, multi-drug, drug-gene, and drug-disease interactions using predictive algorithms individualized down to the DNA. Lifesaving Insights provides subscription-based pharmacogenomic testing and precision clinical pharmacist consultations. The company also offers targeted solutions for specific market segments including Patients and Consumers (with at-home PGx test kits), Providers and Health Systems, ACOs/Payers/Plan Sponsors, Pharmaceutical Companies (ADE Forecasting and Polypharmacy Engagement modules), Hospice Care, and CMS TEAMS Program.

Product and service7 records
1APPRAISE Platform
CategoryMedication Safety Software Platform
Description

Proprietary medication safety assessment platform that analyzes drug-drug, multi-drug, drug-gene, and drug-disease interactions using quasi-mechanistic predictive algorithms to provide comprehensive risk assessments individualized down to the DNA. Targets health systems, payers, ACOs, pharmaceutical companies, and hospice providers.

2Lifesaving Insights
CategorySubscription Pharmacogenomic Service
Description

Subscription-based technology and consulting service providing personalized pharmacogenomic assessments and data analysis from Precision Clinical Pharmacists, with tailored medication recommendations based on individual patient needs and goals. Offered through B2B and B2C channels.

3CMS TEAMS Program Solution
CategoryMedication Therapy Management Program
Description

Medication safety solution designed for CMS (Centers for Medicare & Medicaid Services) TEAMS program requirements, targeting medication therapy management for Medicare beneficiaries.

4Hospice Care Medication Safety Solution
CategoryHospice and Palliative Care Medication Safety
Description

Predictive medication safety analytics and pharmacy solution for hospice providers combining advanced safety analytics with real-time Precision Clinical Pharmacist support for end-of-life medication planning.

5ADE Forecasting for Pharmaceutical Companies
CategoryPharmaceutical Pharmacovigilance Analytics
Description

Cloud-based platform using predictive algorithms to virtually forecast adverse drug event risk for complex polypharmacy patients, providing insights to improve medication persistence and avoid regulatory actions.

6Personalized Comprehensive Polypharmacy Engagement
CategoryPharmaceutical Patient Engagement Service
Description

Precision Clinical Pharmacist-led patient counseling service that virtually adds new drugs to individual medication regimens to support successful drug launches and ensure appropriate medication monitoring.

7Pharmacogenomic (PGx) Test Kit
CategoryPharmacogenomic Test Kit
Description

At-home cheek swab test kit analyzing approximately 100 gene variants that affect how the body interacts with specific medications, used to personalize medication safety assessments.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-06
Description

GalenusRx partnered with Hesperos Inc. through a Small Business Innovative Research (SBIR) grant awarded by the National Institute on Aging, part of the National Institutes of Health. The collaboration advances predictive models addressing anticholinergic concerns in aging populations.

2Florida Association of ACOs (FLAACOs)
Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2025-01-15
Description

FLAACOs announced GalenusRx joined its network as a business partner, connecting GalenusRx with ACOs across Florida to equip them with solutions to identify high-risk patient cohorts and prevent adverse drug events, supporting ACO performance in 2025.

galenusrx.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-03-14
Description

Hannover Life Reassurance Company of America partnered with GalenusRx to provide its healthcare division clients access to GalenusRx's personalized medication safety services. The partnership aims to help clients avoid preventable adverse drug events and reduce insured losses while improving quality and outcomes for policyholders in accountable care and value-based programs.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-02-01
Description

Strategic partnership to launch a genomics-based personalized medication safety program combining pharmacogenomic testing and precision medication consultation to provide personalized medication support plans for healthŌme policyholders, targeting reduction in adverse drug events.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Kadance is listed as a partner on the GalenusRx Partners page. Kadance operates in the pharmacogenomics space and has partnerships including the acquisition of Kailos Genetics. The nature of the partnership with GalenusRx involves complementary pharmacogenomic and medication safety services.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Operates MedWise, a medication safety and polypharmacy decision-support platform; the most direct competitor and the former employer of GalenusRx's two principal founders, with deeper EHR integration and an established payer and provider footprint.

TypeDirect peer
Description

Provides drug-interaction, drug-disease, and clinical decision support databases (MedKnowledge, PatientFirst) used by EHRs and pharmacy systems; comparable core function to APPRAISE in medication safety analytics, though without APPRAISE's genomic layer.

TypeBroad incumbent
Description

Drug data and clinical drug-reference vendor offering drug-interaction screening integrated into major EHRs; competes on the same medication safety decision-support surface but at much broader scale and as part of Wolters Kluwer's healthcare portfolio.

4Elsevier Clinical Solutions (ClinicalPath / ClinicalKey)
TypeBroad incumbent
Description

Provides clinical decision support, drug reference, and care-pathway tools inside hospital workflows; overlaps with APPRAISE's clinical decision support capabilities within a much larger content and analytics portfolio.

5RxRevu (now Clarify)
TypeEmerging player
Description

Prescription benefit decision support and analytics platform serving providers and payers; comparable pharmacy decision-support target customer and similar SaaS model, though not focused on the same genomic-polypharmacy niche.

TypeEmerging player
Description

Pharmacogenomic testing services and partner/competitor in the PGx ecosystem; comparable patient-facing PGx offering and overlapping target customers for the consumer medication-safety pathway.

TypeEmerging player
Description

Precision dosing software leveraging Bayesian and pharmacokinetic models for individual drug optimization; comparable 'individualized-to-the-patient' medication analytics niche and similar SaaS model targeting health systems and pharmacies.

TypeBroad incumbent
Description

Clinical drug information and interaction reference used by hospitals and pharmacists; competes for the same clinical-pharmacy decision-support budget and workflow integration as APPRAISE.

TypeOthers
Description

Pharmacogenomics knowledge base providing curated drug-gene association evidence; not a commercial competitor but a foundational data source and ecosystem participant that powers and validates PGx decision support like APPRAISE.

TypeBroad incumbent
Description

Specialty services and data/analytics for pharma including real-world evidence and clinical trial enablement; comparable pharma-side customers and ADE/pharmacovigilance analytics use cases though at much broader scale and via services rather than GalenusRx's subscription platform.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

GalenusRx

Medication Safety Analyticsgalenusrx.com

GalenusRx is a medication safety technology company that offers the APPRAISE platform, using predictive algorithms to analyze drug-drug, drug-gene, and drug-disease interactions for personalized risk assessment, serving health systems, payers, ACOs, pharmaceutical companies, and consumers via subscription.

What GalenusRx does

GalenusRx, Inc. is a privately held healthcare technology company founded in 2023 and headquartered in Montverde, Florida (incorporated in Delaware). The company develops and commercializes the APPRAISE (Actionable PolyPharmacy Risk Assessment Index for Safety and Efficacy) platform, a proprietary medication safety system that uses quasi-mechanistic predictive algorithms to simultaneously analyze drug-drug, multi-drug, drug-gene, and drug-disease interactions, producing personalized risk assessments individualized to a patient's DNA profile. APPRAISE is delivered primarily through a subscription service called Lifesaving Insights, which combines pharmacogenomic (PGx) testing — an at-home cheek swab analyzing approximately 100 gene variants — with consultations from Precision Clinical Pharmacists who generate tailored medication recommendations.

The company operates a dual-channel go-to-market: enterprise field sales targeting health systems, ACOs, payers, reinsurance intermediaries, pharmaceutical companies, and hospice providers, alongside a direct-to-consumer motion through the company website. Distribution is augmented by strategic channel partnerships with Hannover Re US (reinsurance), healthŌme (PGx testing), Kadance (pharmacogenomics ecosystem), and the Florida Association of ACOs (ACO network). Pricing is subscription-based on an annual billing cadence, with no publicly disclosed price points; enterprise contracts appear to be quote-based.

The business is led by founders Jacques Turgeon (CEO & CSO) and Veronique Michaud (President & COO), both internationally recognized pharmacotherapy researchers with combined $92M+ in research funding and 300+ peer-reviewed publications, alongside co-founder Peter Panageas (CSO/Commercial), Co-CEO Calvin H. Knowlton, Co-Founder Orsula Knowlton, and an advisory board of approximately 9 members including former FDA Office of Clinical Pharmacology Director Lawrence Lesko. The company has raised approximately $8 million across SEC Form D exempt securities offerings in 2024 and 2026, and was awarded an NIH SBIR grant in November 2025. GalenusRx maintains HIPAA compliance and has earned recognition including USA TODAY Network's 2024 Florida Startups to Watch.

GalenusRx firmographics

Firmographics
Name
GalenusRx
Legal name
GalenusRx, Inc.
Website
https://galenusrx.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
11–50 employees
Short description
GalenusRx is a medication safety technology company that offers the APPRAISE platform, using predictive algorithms to analyze drug-drug, drug-gene, and drug-disease interactions for personalized risk assessment, serving health systems, payers, ACOs, pharmaceutical companies, and consumers via subscription.
Ownership category
akta.pro rank

GalenusRx industry classification

Industry
Product category
Medication Safety Analytics
NAICS
Medical Laboratories (621511)
SIC
Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAANAB
Pharmacogenomics (PGx) Decision Support
SECONDARYHLACAKAK
Medication Safety, Pharmacovigilance & Adverse Event Reporting IT
Healthcare & Life Sciences/Digital Health & Health IT/ePrescribing, Medication Management & Pharmacy IT
SECONDARYHLACAKAH
Medication Therapy Management (MTM) & Clinical Pharmacy Services Tools
Healthcare & Life Sciences/Digital Health & Health IT/ePrescribing, Medication Management & Pharmacy IT
SECONDARYHLAFALAN
Pharmacovigilance, Medication Safety & Controlled Substance Diversion Monitoring
Healthcare & Life Sciences/Healthcare Providers & Systems/Pharmacy & Medication Management Services

Keywords

  • Medication safety analytics
  • Pharmacogenomic testing
  • Polypharmacy risk management
  • Adverse drug event prevention
  • Clinical decision support

Where GalenusRx is headquartered

Location

Headquarters

HQ city
Orlando
HQ country
United States
HQ region
North America

Offices1 record

Markets served

GalenusRx business model

Business model
GTM type
B2B and B2C
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Lifesaving Insights Subscription: Subscription-based technology and consulting service providing personalized medication safety assessments, PGx testing interpretation, and ongoing pharmacist consultations. B2B and B2C models depending on channel (direct consumers, health systems, payers, pharma).

Pricing tiers

ModelBillingPrice
SubscriptionAnnualSubscription-based service; specific pricing tiers not publicly disclosed.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels6 records

GalenusRx product offering

Product offering

Core offering

GalenusRx provides a proprietary medication safety assessment platform (APPRAISE) that analyzes drug-drug, multi-drug, drug-gene, and drug-disease interactions to deliver personalized risk scores individualized down to the DNA. Its Lifesaving Insights subscription service combines this platform with at-home pharmacogenomic (PGx) testing and Precision Clinical Pharmacist consultations to prevent adverse drug events, optimize medication regimens, and reduce polypharmacy-related hospitalizations across patients, providers, payers, ACOs, pharmaceutical companies, and hospices.

Product overview

GalenusRx is a medication safety organization offering a unified platform plus modules architecture centered on two core products: the APPRAISE Platform and Lifesaving Insights subscription service. APPRAISE is a proprietary medication safety assessment platform that analyzes drug-drug, multi-drug, drug-gene, and drug-disease interactions using predictive algorithms individualized down to the DNA. Lifesaving Insights provides subscription-based pharmacogenomic testing and precision clinical pharmacist consultations. The company also offers targeted solutions for specific market segments including Patients and Consumers (with at-home PGx test kits), Providers and Health Systems, ACOs/Payers/Plan Sponsors, Pharmaceutical Companies (ADE Forecasting and Polypharmacy Engagement modules), Hospice Care, and CMS TEAMS Program.

Differentiator

Problem solved

Functional benefit

Brands

  • APPRAISE: Actionable PolyPharmacy Risk Assessment Index for Safety and Efficacy - proprietary platform that analyzes drug-drug, multi-drug, drug-gene, and drug-disease interactions to provide comprehensive risk assessment individualized down to DNA.
  • Lifesaving Insights

Products and services

  • APPRAISE Platform Proprietary medication safety assessment platform that analyzes drug-drug, multi-drug, drug-gene, and drug-disease interactions using quasi-mechanistic predictive algorithms to provide comprehensive risk assessments individualized down to the DNA. Targets health systems, payers, ACOs, pharmaceutical companies, and hospice providers.
  • Lifesaving Insights Subscription-based technology and consulting service providing personalized pharmacogenomic assessments and data analysis from Precision Clinical Pharmacists, with tailored medication recommendations based on individual patient needs and goals. Offered through B2B and B2C channels.
  • CMS TEAMS Program Solution Medication safety solution designed for CMS (Centers for Medicare & Medicaid Services) TEAMS program requirements, targeting medication therapy management for Medicare beneficiaries.
  • Hospice Care Medication Safety Solution Predictive medication safety analytics and pharmacy solution for hospice providers combining advanced safety analytics with real-time Precision Clinical Pharmacist support for end-of-life medication planning.
  • ADE Forecasting for Pharmaceutical Companies Cloud-based platform using predictive algorithms to virtually forecast adverse drug event risk for complex polypharmacy patients, providing insights to improve medication persistence and avoid regulatory actions.
  • Personalized Comprehensive Polypharmacy Engagement Precision Clinical Pharmacist-led patient counseling service that virtually adds new drugs to individual medication regimens to support successful drug launches and ensure appropriate medication monitoring.
  • Pharmacogenomic (PGx) Test Kit At-home cheek swab test kit analyzing approximately 100 gene variants that affect how the body interacts with specific medications, used to personalize medication safety assessments.

Quantifiable outcome

  • 3:1 or greater ROI for value-based care clients
  • +3 more outcomes

Companies that use GalenusRx

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles5 records

GalenusRx technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

GalenusRx partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Hesperos Inc.coreStrategic or Co-development Partner · 6 November 2025GalenusRx partnered with Hesperos Inc. through a Small Business Innovative Research (SBIR) grant awarded by the National Institute on Aging, part of the National Institutes of Health. The collaboration advances predictive models addressing anticholinergic concerns in aging populations.
  • Florida Association of ACOs (FLAACOs)coreGTM or Marketing Partner · 15 January 2025FLAACOs announced GalenusRx joined its network as a business partner, connecting GalenusRx with ACOs across Florida to equip them with solutions to identify high-risk patient cohorts and prevent adverse drug events, supporting ACO performance in 2025.
  • Hannover Re UScoreStrategic or Co-development Partner · 14 March 2024Hannover Life Reassurance Company of America partnered with GalenusRx to provide its healthcare division clients access to GalenusRx's personalized medication safety services. The partnership aims to help clients avoid preventable adverse drug events and reduce insured losses while improving quality and outcomes for policyholders in accountable care and value-based programs.
  • healthŌmecoreStrategic or Co-development Partner · 1 February 2024Strategic partnership to launch a genomics-based personalized medication safety program combining pharmacogenomic testing and precision medication consultation to provide personalized medication support plans for healthŌme policyholders, targeting reduction in adverse drug events.
  • KadanceminorStrategic or Co-development PartnerKadance is listed as a partner on the GalenusRx Partners page. Kadance operates in the pharmacogenomics space and has partnerships including the acquisition of Kailos Genetics. The nature of the partnership with GalenusRx involves complementary pharmacogenomic and medication safety services.

Scale indicators4 records

Recent moves6 records

Expansion highlights7 records

GalenusRx competitors and assessment

Company assessment

Direct peers

  • Tabula Rasa HealthCare: Operates MedWise, a medication safety and polypharmacy decision-support platform; the most direct competitor and the former employer of GalenusRx's two principal founders, with deeper EHR integration and an established payer and provider footprint.
  • First Databank (FDB): Provides drug-interaction, drug-disease, and clinical decision support databases (MedKnowledge, PatientFirst) used by EHRs and pharmacy systems; comparable core function to APPRAISE in medication safety analytics, though without APPRAISE's genomic layer.

Broad incumbents

  • Wolters Kluwer (Medi-Span): Drug data and clinical drug-reference vendor offering drug-interaction screening integrated into major EHRs; competes on the same medication safety decision-support surface but at much broader scale and as part of Wolters Kluwer's healthcare portfolio.
  • Elsevier Clinical Solutions (ClinicalPath / ClinicalKey): Provides clinical decision support, drug reference, and care-pathway tools inside hospital workflows; overlaps with APPRAISE's clinical decision support capabilities within a much larger content and analytics portfolio.
  • Lexicomp (Wolters Kluwer): Clinical drug information and interaction reference used by hospitals and pharmacists; competes for the same clinical-pharmacy decision-support budget and workflow integration as APPRAISE.
  • Precision Medicine Group: Specialty services and data/analytics for pharma including real-world evidence and clinical trial enablement; comparable pharma-side customers and ADE/pharmacovigilance analytics use cases though at much broader scale and via services rather than GalenusRx's subscription platform.

Emerging players

  • RxRevu (now Clarify): Prescription benefit decision support and analytics platform serving providers and payers; comparable pharmacy decision-support target customer and similar SaaS model, though not focused on the same genomic-polypharmacy niche.
  • Kailos Genetics (a Kadance company): Pharmacogenomic testing services and partner/competitor in the PGx ecosystem; comparable patient-facing PGx offering and overlapping target customers for the consumer medication-safety pathway.
  • DoseMe: Precision dosing software leveraging Bayesian and pharmacokinetic models for individual drug optimization; comparable 'individualized-to-the-patient' medication analytics niche and similar SaaS model targeting health systems and pharmacies.

Others

  • PharmGKB (Stanford): Pharmacogenomics knowledge base providing curated drug-gene association evidence; not a commercial competitor but a foundational data source and ecosystem participant that powers and validates PGx decision support like APPRAISE.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

GalenusRx social profiles

Digital presence

GalenusRx compliance and trust

Trust signal

Compliance1 record

GalenusRx financial estimates

Financial estimate

Revenue estimate

Valuation estimate

GalenusRx leadership team

Management profile

Number of profiles

Profiles12 records

GalenusRx funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

GalenusRx M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GalenusRx

What does GalenusRx do?

GalenusRx provides a proprietary medication safety assessment platform (APPRAISE) that analyzes drug-drug, multi-drug, drug-gene, and drug-disease interactions to deliver personalized risk scores individualized down to the DNA. Its Lifesaving Insights subscription service combines this platform with at-home pharmacogenomic (PGx) testing and Precision Clinical Pharmacist consultations to prevent adverse drug events, optimize medication regimens, and reduce polypharmacy-related hospitalizations across patients, providers, payers, ACOs, pharmaceutical companies, and hospices.

Is GalenusRx a public or private company?

GalenusRx is a private company. It is classified as venture growth investor backed and is currently operating.

When was GalenusRx founded?

GalenusRx was founded in 2023. It employs 11 to 50 people.

Where is GalenusRx based?

GalenusRx is headquartered in Orlando, United States, in the North America region.

How does GalenusRx make money?

One revenue line is on record: lifesaving Insights Subscription.

Who are GalenusRx's main competitors?

Direct peers on record are Tabula Rasa HealthCare and First Databank (FDB). Broad incumbents are Wolters Kluwer (Medi-Span), Elsevier Clinical Solutions (ClinicalPath / ClinicalKey), Lexicomp (Wolters Kluwer) and Precision Medicine Group. Emerging players are RxRevu (now Clarify), Kailos Genetics (a Kadance company) and DoseMe. PharmGKB (Stanford) is listed as an others.

Does GalenusRx have an API?

No public API is recorded for GalenusRx.

What industry is GalenusRx in?

GalenusRx's product category is Medication Safety Analytics. Its primary akta.pro industry code is HLAAANAB, Pharmacogenomics (PGx) Decision Support, with a secondary code of HLACAKAK, Medication Safety, Pharmacovigilance & Adverse Event Reporting IT. Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireGalenusRx and DartNet Institute Targets Polypharmacy and Strengthens Support for Chronic and Complex Primary CareGalenusRx and DARTNet Institute announced a collaboration to deploy GalenusRx's medication safety tools in primary care practices. The initiative targets polypharmacy and chronic conditions, using APPRAISE to assess drug interactions and reduce potentially inappropriate medications. The partnership aims to improve adherence and lower healthcare utilization.NewswireGalenusRx and Clutch Health Announce Strategic Partnership to Improve Care for Complex Pharma Patients Through Incentive-Based EngagementGalenusRx and Clutch Health announced a strategic partnership to improve care for complex pharmaceutical patients through incentive-based engagement. The collaboration combines GalenusRx's medication safety technology with Clutch Health's behavior orchestration platform to enhance adherence and reduce avoidable healthcare utilization. Both companies plan to scale offerings across Medicaid initiatives, payers, providers, and employer groups.SecSEC FORM DGalenusRx, Inc. filed a Form D with the U.S. Securities and Exchange Commission for an exempt offering of securities under Rule 506(b). The filing indicates that the company has sold $6,875,647 worth of equity securities to 100 investors out of a total offering amount of approximately $8.03 million.GalenusrxhealthŌme and GalenusRx Forge Strategic Partnership to Launch Genomics-based Personalized Medication Safety ProgramhealthŌme and GalenusRx announced a strategic partnership to launch a genomics-based personalized medication safety program aimed at reducing adverse drug events. The initiative integrates healthŌme’s pharmacogenomic testing with GalenusRx’s precision clinical pharmacy expertise to optimize medication regimens for policyholders, particularly those managing cancer or autoimmune diseases. This collaboration seeks to improve individual health outcomes by leveraging DNA insights to inform proactive healthcare decisions.TmcnetHannover Re US Partners with GalenusRx for Personalized, Precision Medication Safety ServicesHannover Re US announced a partnership with GalenusRx to provide medication safety services to healthcare clients. The collaboration uses GalenusRx's APPRAISETM platform and Lifesaving Insights consulting to reduce adverse drug events and lower medical expenses. The partnership aims to support value-based care programs and reduce insured losses.